Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology
17 Mayo 2024 - 1:30PM
Kamari Pharma, a privately-held clinical stage biotechnology
company developing first and best-in-class treatments for rare and
severe genetic skin diseases, today announced two presentations
reporting results for its novel TRPV3 inhibitors, KM-001 (topical)
and KM-023 (oral), were given at the 81st Annual Meeting of the
Society for Investigative Dermatology (SID) that is taking place
May 15-18, 2024 in Dallas, TX, USA.
Below are summaries of the presentations:
Poster #LB941: “KM-001, a novel TRPV3
inhibitor, demonstrates safety and preliminary efficacy in Phase 1b
clinical study for the treatment of palmoplantar
keratoderma” presented by Edel O’Toole, M.D., Ph.D.
Professor of Molecular Dermatology and Centre Lead of the Centre
for Cell Biology and Cutaneous Research, Blizard Institute, Queen
Mary University of London and lead investigator in the study.
- Presented
results from twelve-week, Phase 1b open-label studies (UK and
Israel) assessing 4g/day of KM-001 1% cream applied to each foot
twice daily for the treatment of pachyonychia congenita (PC) and
punctate palmoplantar keratoderma type 1 (PPPK1). Eight patients in
the UK (7 PC;1 PPPK1) and seven patients in Israel (3 PC;4 PPPK1)
completed the treatment period.
- Safety: No
drug-related severe adverse events nor systemic side effects were
observed. Minimal treatment emergent adverse events occurred
(n=11); all were mild and did not lead to patient
discontinuation.
- Efficacy:
Responder rate at the end of treatment was 88% (CI 52.9-97.8%) in
UK (n=8) and 86% (CI 48.7-97.4%) in Israel (n=7), as defined by an
improvement in at least one of six pre-defined disease parameters.
Additionally, 47% of patients improved in at least two parameters
with a disease severity reduction trend and pain score measured by
VAS was reduced in 60% of PC patients; PPPK1 patients do not have
pain as a symptom.
Presentation #771: “Novel TRPV3
inhibitors developed for the treatment of palmoplantar
keratodermas, demonstrate safety and efficacy in preclinical
models” presented by Liora Braiman-Wiksman, Ph.D., Chief
Scientific Officer at Kamari.
- Presented
preclinical results for KM-001 and KM-023, Kamari’s specific and
highly selective TRPV3 inhibitors designed to address both
molecular and local damage to the skin by regulating Ca²⁺ influx
into the cell.
- In 3D skin
models of PC and PPPK1, KM-001 and KM-023 normalized proliferation
and differentiation markers and enhanced epidermal barrier
formation.
- In in vivo
efficacy studies performed in DS-Nh mice, a gain-of-function TRPV3
mutation model, KM-001 showed significant improvement in skin
histology vs vehicle (70% vs 30%) and exhibited significant
reduction in scratching bouts (80%, p>0.04) and KM-023 showed a
significant reduction in keratoderma severity score (p=0.003) and
reduced scratching significantly (p<0.001) vs vehicle.
Based on these results, Kamari plans to initiate
Phase 2 development of KM-001 for the treatment of palmoplantar
keratoderma and advance KM-023 into first-in-human studies for the
oral treatment of Olmstead syndrome, severe keratoderma and
Ichthyosis.
The full content of these posters is available
in the News page of Kamari's corporate website
(https://kamaripharma.com/category/news).
About Kamari Pharma
Kamari Pharma is a privately-held clinical stage
biotechnology company developing first and best in class treatments
for rare and severe genetic skin diseases. Kamari’s lead molecules,
KM-001 (topical) and KM-023 (oral) are novel, highly specific and
selective TRPV3 inhibitors that are initially being developed to
treat palmoplantar keratodermas, Olmstead syndrome and Ichthyosis.
Kamari’s management team is comprised of industry leaders highly
experienced in drug discovery, dermatological pharmaceutical
development and rare disease drug development.
Contact Information
Investors and MediaMarcy NanusManaging PartnerTrilon Advisors,
LLCmnanus@trilonadvisors.com